搜索结果
靶点ID:TCMBANKGE001050
靶点别名:APKD2; PC2; PKD4; Pc-2; TRPP2
靶点描述:polycystin 2, transient receptor potential cation channel
染色体:4
染色体位置:4q22.1
靶点类型:protein-coding
HERB_ID:HBTAR003017
HGNC_Link:9009
OMIM_Link:173910
Ensembl_Link:ENSG00000118762
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000015 | brefeldin a | (7S,15S,1R)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-o ne; AC1O5L8S; AKOS024282481; SR-01000597412-1; MolPort-004-955-162; NCGC00025061-02; UPCMLD-DP095:002; NCGC00025061-03; IDI1_033950; (2E,7S,10E,12R,13R,15S)-12,15-dihydroxy-7-methyl-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-9-one; SR-01000597412; HMS1361J22; 1,6,7,8,9,11a?,12,13,14,14?a-Decahydro-1?,13?-dihydroxy-6?-methyl-4H-cyclopent(f)oxacyclotridecin-4-one; ST056354; UPCMLD-DP095; 4H-Cyclopent(f)oxacyclotridecin-4-one,1,6,7,8,9,11a-beta,12,13,14,14a-alpha-decahydro-1-beta-13-alpha-dihydroxy-6-beta-methyl-; LS-58416; CCG-208020; NSC-89671; NSC 56310; 1,6,7,8,9,11a,12,13,14,14a-Decahydro-1,13-dihydroxy-6-methyl-4H-cyclopent[f]oxacyclotridecin-4-one; (1R,6S,13S,14AR)-1,13-DIHYDROXY-6-METHYL-1H,6H,7H,8H,9H,11AH,12H,13H,14H,14AH-CYCLOPENTA[F]OXACYCLOTRIDECAN-4-ONE; HMS1989J22; 4H-Cyclopent(f)oxacyclotridecin-4-one, 1,6,7,8,9,11a-beta,12,13,14,14a-alpha-decahydro-1-beta-13-alpha-dihydroxy-6-beta-methyl-; NCGC00017254-03; CHEMBL1572153; HMS3402J22; HMS1791J22; UPCMLD-DP095:001; NCGC00017254-04; brefeldin A; Cyanaein; G405; 20350-15-6; SCHEMBL12648486; Cyanein; BSPBio_001480; Decumbin; (+)-Brefeldin A, Eupenicillium brefeldianum; C16H24O4 | C16H24O4 | 280.36 g/mol | CC1CCCC=CC2CC(CC2C(C=CC(=O)O1)O)O |
| TCMBANKIN036913 | naringenin | (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; ZINC1785; Spectrum2_000325; 2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; (-)-Naringenin; SDCCGMLS-0066570.P001; (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one; MLS000574861; KBio2_000727; CHEBI:50201; HMS3468H18; ALBB-015405; NCGC00017346-01; BBL010488; AJ-08090; DivK1c_000118; BB 0261506; (S)-2,3-dihydo-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; CAS-480-41-1; KBio3_001454; SC-85987; 4H-1-benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2R)-; AIDS-001417; NINDS_000118; SCHEMBL17166263; Spectrum3_000567; 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; (2R)-naringenin; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-chromanone; BSPBio_001954; BB_NC-1001; MCULE-5852778653; NCGC00163598-01; BG01564988; MFCD03265520; naringenin ; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)-; (2R)-5,7,4'-trihydroxyflavone; AKOS004119880; CHEBI:17846; ST24036200; AC1LDI7C; KBioGR_000508; ZINC00156701; Phytochemistry 8: 127 (1969); R6691; Asahina; 4',5, 7-Trihydroxyflavanone; N1370; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; C00509; 480-41-1; KBio2_003295; (2R)-4',5,7-trihydroxyflavanone; (+)-naringenin; Spectrum_000247; ZB000410; NAR; pelargidanon 1602; (R)-naringenin; IDI1_000118; STK801623; Spectrum5_001423; MolPort-002-507-277; Spectrum4_000124; 17654-19-2; KBio1_000118; KBioSS_000727; (+)-(2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; (2R)-4',5,7-trihydroxyflavan-4-one; NCGC00016457-01; STOCK1N-05989; KBio2_005863; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; AIDS001417; BG00617674; TNP00287; (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; SPECTRUM1500746; YSO1; SMR000156272; 4',5,7-triOH-Flavone; SPBio_000329 | C15H12O5 | 272.253 | c1(O[H])c([H])c([H])c([C@]2([H])Oc(c([H])c(O[H])c([H])c3O[H])c3C(=O)C2([H])[H])c([H])c1[H] |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000009 | Neoplasms | Abnormality of the nervous system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI000049 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI002742 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | group | |
| TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI004054 | Pathological Conditions, Signs and Symptoms | - | Neoplastic Process | phenotype | |
| TCMBANKDI004646 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI007520 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
| TCMBANKDI009657 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases | Abnormality of the cardiovascular system | Congenital Abnormality | group | |
| TCMBANKDI009951 | Nutritional and Metabolic Diseases; Musculoskeletal Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI010301 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system | Disease or Syndrome | disease | |
| TCMBANKDI012481 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI013089 | Cardiovascular Diseases | Abnormality of the cardiovascular system | Finding | phenotype | |
| TCMBANKDI013171 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hemic and Lymphatic Diseases; Cardiovascular Diseases | Growth abnormality | Congenital Abnormality | disease | |
| TCMBANKDI013541 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI014359 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | - | Congenital Abnormality | group | |
| TCMBANKDI020764 | Digestive System Diseases | Abnormality of the digestive system | Disease or Syndrome | group | |
| TCMBANKDI021303 | Pathological Conditions, Signs and Symptoms; Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome; Congenital Abnormality | disease | |
| TCMBANKDI023416 | Pathological Conditions, Signs and Symptoms; Digestive System Diseases; Neoplasms | Abnormality of the digestive system | Disease or Syndrome | disease | |
| TCMBANKDI025850 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI027026 | Neoplasms; Skin and Connective Tissue Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI028459 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Abnormality of the digestive system; Abnormality of the cardiovascular system; Growth abnormality | Congenital Abnormality | disease | |
| TCMBANKDI029813 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI030288 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI030377 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Immune System Diseases; Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI031189 | Neoplasms | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease |
滇IICP备16009434号-1 |
Dai SX Lab